ReviewTissue barriers2021
The claudin-transcription factor signaling pathway.
Review in Tissue barriers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Dietary Zinc Supplementation Improves Growth, Antioxidant Capacity, Immunity, and Intestinal Health in Juvenile Black Carp (Biology · 2026Article
- The IQGAP1-Claudin4-JNK Signaling Axis as a Differential Biomarker in Renal Cell Carcinoma.Clinical and translational science · 2026Article
- Cldn11 deficiency aggravates osteoarthritis by inhibiting Notch signalling in a Tspan5-dependent manner.Journal of orthopaedic surgery and research · 2026Article
- A Novel Tight Junction-Nuclear Receptor Signaling Pathway Regulating Cancer Progression.Pathology international · 2025Review
- Claudin Proteins: Their Potential Role in Obesity and Adipose Tissue Signaling, Physiology and Disease.Nutrients · 2025Review
- IgSF11-RAP1 signaling promotes cell migration and invasion of cutaneous melanoma.Cell communication and signaling : CCS · 2025Article
- Abnormal phosphorylation of human LRH1 at Ser510 predicts poor prognosis and promotes cell viability in lung squamous cell carcinoma.BMC cancer · 2025Article
- CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma.Frontiers in pharmacology · 2025Review
- CLDN22 Serves as a Novel Prognostic Biomarker and Immunotherapy Response Predictor in Gliomas: A Comprehensive Multiomics Analysis.International journal of genomics · 2025Article
- Extrajunctional CLDN10 cooperates with LAT1 and accelerates clear cell renal cell carcinoma progression.Cell communication and signaling : CCS · 2024Article
- Claudin2 is involved in the interaction between Megalocytivirus-induced virus-mock basement membrane (VMBM) and lymphatic endothelial cells.Veterinary research · 2024Article
- [Research progress of type 2 inflammation-related tissue remodeling in nasal polyps].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2024Review
- Micronutrients at Supplemental Levels, Tight Junctions and Epithelial Barrier Function: A Narrative Review.International journal of molecular sciences · 2024Review
- Transcriptional Levels of Intercellular Junction Proteins in an Alveolar Epithelial Cell Line Exposed to Irradiation or Bleomycin.Bulletin of experimental biology and medicine · 2024Article
- Claudins: from gatekeepers of epithelial integrity to potential targets in hepato-pancreato-biliary cancers.Frontiers in oncology · 2024Review
- Aberrant phosphorylation of human LRH1 at serine 510 is predictable of hepatocellular carcinoma recurrence.Clinical and experimental medicine · 2023Article
- Article
- Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor β.Breast cancer research : BCR · 2023Article
- Androgen receptor variant 7 exacerbates hepatocarcinogenesis in a c-MYC-driven mouse HCC model.Oncogenesis · 2023Article
- Claudin‑9 is a novel prognostic biomarker for endometrial cancer.International journal of oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Claudins (CLDNs) represent major transmembrane proteins of tight junctions and contribute to the barrier function. They also serve as anchors for several signaling proteins, but the underlying molecular basis has yet to be established. The present review covers the recent progress in our understanding of the CLDN signaling pathway in health and disease. We discuss the functional relevance of phosphotyrosine motifs in the C-terminal cytoplasmic domain of CLDNs and define mutual regulation between CLDNs and Src-family kinases (SFKs). In addition, we focus on the crosstalk between CLDN and transcription factor signaling. We also describe how aberrant CLDN-transcription factor signaling promotes or inhibits cancer progression. We propose that a link between various cell adhesion molecules and transcription factors coordinates a range of physiological and pathological events via activation or suppression of target genes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.